COVICEL

Call: COVID-19

Reference No.: CO-2020/00003

Project financed by the Department of Economic Development and Infrastructures of the Basque Government.

Histocell has been involved in contributing its knowledge and experience in finding solutions to address the COVID-19 health emergency through a cell therapy drug based on preconditioned adipose tissue mesenchymal cells, called HC016, for critically ill patients in the Intensive Care Unit with ARDS, the most severe complication of COVID-19 infection.

Thus, the objective of the project is to conduct a phase 1/2 clinical study of the cellular drug HC016 in patients with Acute Respiratory Distress Syndrome (ARDS) caused by COVID-19. This is intended to reduce pulmonary inflammation and overcome ARDS, avoid the establishment of irreversible damage to the alveolar tissue, thus improving the clinical situation and the patient’s quality of life.